Document is current
Any future updates will be listed below
-
Authors
Generali, M. https://orcid.org/0000-0001-8396-3256
Kehl, D.
Meier, D.
Zorndt, D.
Atrott, K.
Saito, H.
Emmert, MY.
Hoerstrup, SP.
-
Funding
Funding for this research was provided by:
Mäxi-Stiftung (Mäxi-Stiftung)
CiRA Foundation (CiRA Foundation)
- License Information
-
More Information
Article History
Received: 6 December 2024
Accepted: 7 April 2025
First Online: 18 April 2025
Declarations
:
: Human peripheral blood was collected with written informed consent according to the permission from the cantonal ethics commission of Zurich, Switzerland [KEK-ZH-2014-0430] entitled “Periphere mononukleäre Blutzellen als Quelle für Tissue Engineering in der Regenerativen Medizin” (Amendmend 05.01.2015).The veterinary office of the Canton Zurich, Switzerland approved all animal experiments (ZH174/2020) entitled “Safety assessment of induced pluripotent stem cell-derived cardiomyocytes” (approved 19.02.2021).
: All authors agreed to publication.
: S.P.H. is a shareholder at Xeltis BV and LifeMatrix Technologies AG. M.Y.E. is a shareholder at LifeMatrix Technologies AG. H.S. is the investigator of a record listed on a patent application (PCT/JP2017/023513, filed by Kyoto University on 27 June 2017) related to the design of the RNA-ON switch. H.S. is listed on a patent application (Japanese patent application no. 2021-177971) related to the cell purification. H.S. own shares of aceRNA Technologies Ltd, where H.S. is an outside director. The authors declare that they have no other competing interests.
